BioXcel Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.7M
Doctors Paid
2,768
Transactions
5,408
2024 Total
$5.2M
Payment Breakdown by Category
Research$8.5M (88.2%)
Consulting$420,398 (4.3%)
Food & Beverage$159,119 (1.6%)
Travel$91,244 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 161 | 88.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,983 | 184 | 4.7% |
| Consulting Fee | $420,398 | 52 | 4.3% |
| Food and Beverage | $159,119 | 4,205 | 1.6% |
| Travel and Lodging | $91,244 | 794 | 0.9% |
| Honoraria | $12,690 | 12 | 0.1% |
Payments by Type
Research
$8.5M
161 transactions
General
$1.1M
5,247 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA | $2.3M | 0 | 18 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $2.0M | 0 | 16 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $1.5M | 0 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 OF AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $1.2M | 0 | 11 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype | $457,648 | 0 | 41 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | $456,719 | 0 | 44 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $448,946 | 0 | 4 |
| EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | $91,092 | 0 | 3 |
| BXCL501401 | $81,795 | 0 | 14 |
Payments by Medical Specialty
Top Paid Doctors — Page 111
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Darin Wilson, Md, MD | Hospitalist | Atlanta, GA | $12.84 | $0 |
| Frank Perkins, M.d, M.D | Psychiatry | Jackson, MS | $12.83 | $0 |
| Robert Wasson, M.d, M.D | Emergency Medicine | Bowling Green, KY | $12.78 | $0 |
| Dr. Adam Miller, Md, MD | Family Medicine | Lawrenceburg, IN | $12.78 | $0 |
| Mrs. Mckayla Basham, Aprn, APRN | Nurse Practitioner | Cecilia, KY | $12.78 | $0 |
| Dr. Michael De Boer, M.d, M.D | Emergency Medicine | Knoxville, TN | $12.78 | $0 |
| Dr. Joshua Pedigo, M.d, M.D | Emergency Medicine | Bowling Green, KY | $12.78 | $0 |
| Bruce Greenberg, Md, MD | Family Medicine | Summersville, WV | $12.75 | $0 |
| Laura Leistiko, M.d, M.D | Emergency Medicine | Simi Valley, CA | $12.72 | $0 |
| Daniella Garcia, Md, MD | Emergency Medicine | Hemet, CA | $12.72 | $0 |
| Akshat Saggar, D.o, D.O | Psychiatry | Largo, FL | $12.71 | $0 |
| Ruth Mugo | Psychiatric/Mental Health | Columbia, MO | $12.71 | $0 |
| Mr. Gordon Kusi, Apn, APN | Adult Health | Belle Mead, NJ | $12.71 | $0 |
| Abimbola Omoruyi | Psychiatric/Mental Health | Belle Mead, NJ | $12.71 | $0 |
| Shailaja Shah, Md, MD | Geriatric Psychiatry | Hillsborough, NJ | $12.71 | $0 |
| Dr. Anu Upadhyay, Md, MD | Psychiatry | Piscataway, NJ | $12.71 | $0 |
| Jagwinder Sandhu, Md, MD | Psychiatry | Belle Mead, NJ | $12.71 | $0 |
| Dr. Abdul Kazi, M.d, M.D | Psychiatry | West Trenton, NJ | $12.71 | $0 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. has made $9.7M in payments to 2,768 healthcare providers, recorded across 5,408 transactions in the CMS Open Payments database. In 2024, the company paid $5.2M. The top product by payment volume is IGALMI ($8.7M).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Psychiatry ($395,547 to 540 doctors).
Payment categories include: Food & Beverage ($159,119), Consulting ($420,398), Research ($8.5M), Travel & Lodging ($91,244).
BioXcel Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.